Issue 5, 2024

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Abstract

This article presents bioconjugates combining nanoparticles (AGuIX) with nanobodies (VHH) targeting Programmed Death-Ligand 1 (PD-L1, A12 VHH) and Cluster of Differentiation 47 (CD47, A4 VHH) for active tumor targeting. AGuIX nanoparticles offer theranostic capabilities and an efficient biodistribution/pharmacokinetic profile (BD/PK), while VHH's reduced size (15 kDa) allows efficient tumor penetration. Site-selective sortagging and click chemistry were compared for bioconjugation. While both methods yielded bioconjugates with similar functionality, click chemistry demonstrated higher yield and could be used for the conjugation of various VHH. The specific targeting of AGuIX@VHH has been demonstrated in both in vitro and ex vivo settings, paving the way for combined targeted immunotherapies, radiotherapy, and cancer imaging.

Graphical abstract: AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Supplementary files

Article information

Article type
Paper
Submitted
21 Sept. 2023
Accepted
20 Nov. 2023
First published
06 Dec. 2023

Nanoscale, 2024,16, 2347-2360

AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

L. Carmès, G. Bort, F. Lux, L. Seban, P. Rocchi, Z. Muradova, A. Hagège, L. Heinrich-Balard, F. Delolme, V. Gueguen-Chaignon, C. Truillet, S. Crowley, E. Bello, T. Doussineau, M. Dougan, O. Tillement, J. D. Schoenfeld, N. Brown and R. Berbeco, Nanoscale, 2024, 16, 2347 DOI: 10.1039/D3NR04777F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements